Date: 2015-01-19
Type of information: Collaboration agreement
Compound: dipraglurant
Company: Addex Therapeutics (Switzerland) Dystonia Medical Research Foundation (USA - IL)
Therapeutic area: Neurological diseases
Type agreement: collaboration
Action mechanism: mGluR5 negative allosteric modulator. Dipraglurant is an oral, small molecule allosteric modulator that inhibits selectively the metabotropic glutamate receptor 5 (mGluR5), a Class C G-Protein Coupled Receptor (GPCR), with potential to be used in combination with levodopa or dopamine agonists or as a standalone treatment for Parkinson\'s disease levodopa-induced dyskinesia (PD-LID), motor and non-motor symptoms of Parkinson\'s disease and other movement disorders. In a double-blind, placebo-controlled, US and European Phase 2 study in PD-LID, data showed that dipraglurant met the primary objective of the study by exhibiting a good safety and tolerability profile. Dipraglurant also demonstrated a statistically significant reduction in LID severity with both 50 and 100 mg doses. Dipraglurant reduced dystonia severity in addition to chorea, the two major LID components. Efficacy was measured using the modified Abnormal Involuntary Movement Scale (mAIMS), patient diaries documenting \"off-time\" (impaired voluntary movement), \"on-time\" (with or without dyskinesia) and sleep. Additional endpoints include the Unified Parkinson\'s Disease Rating Scale (UPDRS), the Clinician & Patient Global Impression of Change (CGIC & PGIC), and an evaluation of the patients\' mood using the Hospital Anxiety & Depression Score. The trial was supported by a grant from The Michael J. Fox Foundation for Parkinson\'s Research.
Disease: dystonia
Details: * On January 19, 2015, Addex Therapeutics, a Swiss company pioneering allosteric modulation-based drug discovery and development and the Dystonia Medical Research Foundation (DMRF) announced entering a collaboration to explore the use of dipraglurant to treat dystonia, the third most common movement disorder following essential tremor and Parkinson\'s disease. Dipraglurant, a novel small molecule inhibitor of the metabotropic glutamate receptor 5, has shown promise in the treatment of levodopa-induced dyskinesia and dystonia in Parkinson\'s disease. Dipraglurant has also been shown to normalize the effects of the TOR1A/DYT1 dystonia mutation in the brains of mice. The objective of the collaboration is to design a detailed development plan and regulatory path as well as identifying key option leaders and patients for a Phase 2 clinical trial. In addition, Addex recently reported on 9 January, plans to start clinical testing of the therapeutic effect of dipraglurant in patients with cervical dystonia in collaboration with Professor Dirk Dressler of The Hannover Medical School.
Financial terms:
Latest news:
